HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT) Files An 8-K Regulation FD Disclosure

Item7.01Regulation FD Disclosure

On June28, 2017, Helius Medical Technologies, Inc. (the Company)
issued a press release announcing the closing of a CAD
$7.0million (US$ 5,275,900) private placement. A copy of the
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K (this Report).

The information in this Report, including Exhibit 99.1 hereto, is
furnished to Item 7.01 and shall not be deemed filed for purposes
of Section18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that Section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing. The Companys submission of this Report shall
not be deemed an admission as to the materiality of any
information required to be disclosed solely to satisfy the
requirements of Regulation FD.

This Report and Exhibit 99.1 hereto contain forward-looking
statements within the meaning of the federal securities laws.
These forward looking statements are based on current
expectations and are not guarantees of future performance.
Further, the forward-looking statements are subject to the
limitations listed in Exhibit 99.1 and in the other reports of
the Company filed with the Securities and Exchange Commission,
including that actual events or results may differ materially
from those in the forward-looking statements.

(d)Exhibits

2

HELIUS MEDICAL TECHNOLOGIES, INC. Exhibit
EX-99.1 2 d411240dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Helius Medical Announces Closing of CAD$7.0 Million Private Placement NEWTOWN,…
To view the full exhibit click here
About HELIUS MEDICAL TECHNOLOGIES, INC. (OTCMKTS:HSDT)

Helius Medical Technologies, Inc. is a medical technology company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company is engaged in the development of its product, the portable neuromodulation stimulator (PoNS) device. The device, when used in combination with physiotherapy, is designed to enhance the brain’s ability to compensate for damage due to trauma or disease. The Company’s PoNS device is designed to induce cranial nerve non-invasive neuromodulation through an increase in stimulation of the facial and trigeminal nerves, which innervate the tongue. The PoNS device is developed to deliver to the tongue a non-invasive neurostimulation, in a form that induces neuromodulation. The PoNS device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue.